Dapivirine is a non-nucleoside reverse transcriptase inhibitor (NNRTI) that is currently in clinical trials as a prophylactic against HIV infection. In various models such as dendritic cells and T cells, dapivirine exhibits antiviral activity by suppressing viral replication.
| Cas No. | 244767-67-7 |
|---|---|
| Purity | ≥98% |
| Formula | C20H19N5 |
| Formula Wt. | 329.41 |
| IUPAC Name | 4-{[4-(Mesitylamino)-2-pyrimidinyl]amino}benzonitrile |
| Synonym | TMC120 |
| Store Temp | -20°C |
|---|---|
| Ship Temp | Ambient |
| Info Sheet | D0261 Info Sheet PDF |
|---|---|
| Brochures | Antivirals Booklet |
Devlin B, Nuttall J, Wilder S, et al. Development of dapivirine vaginal ring for HIV prevention. Antiviral Res. 2013 Dec;100 Suppl:S3-8. PMID: 24188702.
Gupta SK, Nutan. Clinical use of vaginal or rectally applied microbicides in patients suffering from HIV/AIDS. HIV AIDS (Auckl). 2013 Oct 22;5:295-307. PMID: 24174883.
Njai HF, Lewi PJ, Janssen CG, et al. Pre-incubation of cell-free HIV-1 group M isolates with non-nucleoside reverse transcriptase inhibitors blocks subsequent viral replication in co-cultures of dendritic cells and T cells. Antivir Ther. 2005;10(2):255-62. PMID: 15865220.
Van Herrewege Y, Michiels J, Van Roey J, et al. In vitro evaluation of nonnucleoside reverse transcriptase inhibitors UC-781 and TMC120-R147681 as human immunodeficiency virus microbicides. Antimicrob Agents Chemother. 2004 Jan;48(1):337-9. PMID: 14693562.
